ATE480243T1 - Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems - Google Patents
Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystemsInfo
- Publication number
- ATE480243T1 ATE480243T1 AT05764495T AT05764495T ATE480243T1 AT E480243 T1 ATE480243 T1 AT E480243T1 AT 05764495 T AT05764495 T AT 05764495T AT 05764495 T AT05764495 T AT 05764495T AT E480243 T1 ATE480243 T1 AT E480243T1
- Authority
- AT
- Austria
- Prior art keywords
- useful
- cns
- acute
- diagnosis
- composition
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 title abstract 2
- 208000001738 Nervous System Trauma Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000009692 acute damage Effects 0.000 abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000002025 microglial effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000001067 neuroprotector Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401628 | 2004-06-23 | ||
| PCT/ES2005/000357 WO2006000608A1 (es) | 2004-06-23 | 2005-06-23 | Uso de bloqueantes del canal de katp (kcc), en especial sulfonilureas como la glibenclamida, para el tratamiento del daño agudo del sistema nervioso central causado por distintas enfermedades |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480243T1 true ATE480243T1 (de) | 2010-09-15 |
Family
ID=35781576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05764495T ATE480243T1 (de) | 2004-06-23 | 2005-06-23 | Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070203239A1 (de) |
| EP (1) | EP1782815B1 (de) |
| JP (1) | JP2008503549A (de) |
| AT (1) | ATE480243T1 (de) |
| AU (1) | AU2005256676A1 (de) |
| CA (1) | CA2571718A1 (de) |
| DE (1) | DE602005023489D1 (de) |
| ES (1) | ES2352203T3 (de) |
| WO (1) | WO2006000608A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438913B1 (de) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | Nicht-selektiver Kationenkanal in neuralen Zellen und Verfahren zur Behandlung von Hirnschwellung |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| JP5085326B2 (ja) | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
| EP1802313B1 (de) * | 2004-09-18 | 2010-11-03 | University of Maryland, Baltimore | Therapeutische mittel zum targeting des ncca-atp-kanals und verwendungsverfahren dafür |
| EP1884244A1 (de) | 2006-08-02 | 2008-02-06 | Assistance Publique - Hopitaux de Paris | Kalium-Kanal Liganden zur Behandlung von Diabetes und neuropsychologischen Störungen |
| US9511075B2 (en) | 2007-01-12 | 2016-12-06 | The University Of Maryland, Baltimore | Targeting NCCA-ATP channel for organ protection following ischemic episode |
| EP2114160B1 (de) * | 2007-02-09 | 2016-11-16 | University of Maryland, Baltimore | Antagonisten eines nicht selektiven kationenkanals in nervenzellen |
| CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
| US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| EP2609914A1 (de) * | 2011-12-29 | 2013-07-03 | Universitätsklinikum Hamburg-Eppendorf | Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4444860A1 (de) * | 1994-12-16 | 1996-06-20 | Bayer Ag | Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel |
| US6147098A (en) * | 1998-05-11 | 2000-11-14 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| EP2438913B1 (de) * | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | Nicht-selektiver Kationenkanal in neuralen Zellen und Verfahren zur Behandlung von Hirnschwellung |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| WO2004093811A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage |
| WO2004093816A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent |
| WO2004093896A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage |
| JP2007505142A (ja) * | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| JP5085326B2 (ja) * | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
-
2005
- 2005-06-23 US US11/630,420 patent/US20070203239A1/en not_active Abandoned
- 2005-06-23 JP JP2007517311A patent/JP2008503549A/ja not_active Withdrawn
- 2005-06-23 DE DE602005023489T patent/DE602005023489D1/de not_active Expired - Lifetime
- 2005-06-23 AU AU2005256676A patent/AU2005256676A1/en not_active Abandoned
- 2005-06-23 ES ES05764495T patent/ES2352203T3/es not_active Expired - Lifetime
- 2005-06-23 AT AT05764495T patent/ATE480243T1/de not_active IP Right Cessation
- 2005-06-23 CA CA002571718A patent/CA2571718A1/en not_active Abandoned
- 2005-06-23 EP EP05764495A patent/EP1782815B1/de not_active Expired - Lifetime
- 2005-06-23 WO PCT/ES2005/000357 patent/WO2006000608A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1782815B1 (de) | 2010-09-08 |
| WO2006000608A1 (es) | 2006-01-05 |
| EP1782815A1 (de) | 2007-05-09 |
| ES2352203T3 (es) | 2011-02-16 |
| JP2008503549A (ja) | 2008-02-07 |
| AU2005256676A1 (en) | 2006-01-05 |
| US20070203239A1 (en) | 2007-08-30 |
| DE602005023489D1 (de) | 2010-10-21 |
| CA2571718A1 (en) | 2006-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| DK1409544T3 (da) | Humane DR4-antistoffer og anvendelser deraf | |
| WO2004037204A3 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| ATE413902T1 (de) | Patientenüberwachungssystem | |
| EP2006298A3 (de) | Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon | |
| PL1615952T3 (pl) | Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2 | |
| ATE480243T1 (de) | Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems | |
| BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
| DE60027415D1 (de) | Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält | |
| WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
| IL181286A0 (en) | Methods of healing wounds by administering human il-18 | |
| WO2007112355A3 (en) | Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders | |
| WO2007133746A3 (en) | Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival | |
| ATE453627T1 (de) | Herstellung von verbindungen zur bestimmung der hypoxie | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE553763T1 (de) | Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern | |
| WO2002062205A3 (en) | Methods for diagnosing and treating heart disease | |
| SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice | |
| EP2096120A3 (de) | Verwendung sekretierter Proteinprodukte zur Prävention und Behandlung von Erkrankungen der Bauchspeicheldrüse und/oder Adipositas und/oder des metabolischen Syndroms | |
| WO2003001877A3 (en) | Methods for the diagnosis and treatment of cardiac tissue rejection | |
| WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
| PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny | |
| WO2002062204A3 (en) | Methods for diagnosing and treating heart disease | |
| EP1661578A4 (de) | Mittel zur prävention und heilung von hautgeschwüren mit humanem rekombinantem hgf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |